EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Subcutaneous Allergen Immunotherapy in Adults Allergic to House Dust Mites: A Phase 3 Randomized Controlled Trial

Claus Bachert iD, Hans Hoogeveen, Rimko Ten Have iD, Donghui Yu iD, Margitta Worm iD, Oliver Pfaar iD, Marek Jutel iD, Andreas Distler, Andrzej Bozek iD, Dirk-Jan Opstelten, Annemie Narkus, Ronald van Ree

Allergy · 2025

DOI: 10.1111/all.70063 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Allergy, 2025. Verfasst von Claus Bachert und 11 weiteren Autor:innen. Beteiligte Einrichtung: ENT-Dep, University of Muenster, Muenster, Germany. Hauptthemen laut MEDLINE: Desensitization, Immunologic, Pyroglyphidae, Antigens, Dermatophagoides, Hypersensitivity. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: HAL Allergy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Subcutaneous allergen immunotherapy (SCIT) has a longstanding history as a safe and effective treatment. Nevertheless, to meet the European Medicines Agency's regulatory requirements for continued market authorization, its efficacy and safety must be confirmed in a pivotal Phase III trial.

Objective

Based on a successful Phase II dose‐finding study, the aim was to confirm the safety and efficacy of a subcutaneous house dust mites (HDM) preparation in a randomized controlled trial using an optimal higher dose than the current maintenance dose.

Method

Seven hundred sixty‐seven subjects were randomized in a 1:1 ratio to 1‐year treatment with SCIT‐product at a dose of 50,000 AUeq/mL or placebo. Out of these, 682 subjects completed the study. The primary endpoint was assessed using the combined symptom and medication score (CSMS(n)), which focuses on nasal symptoms, as specified by the European Academy of Allergy and Clinical Immunology (EAACI).

Results

The primary endpoint showed a trend ( p = 0.0767) with a mean treatment effect of −0.12 (95% CI, −0.3 to 0) toward a favorable change in mean CSMS(n) for active compared to placebo treatment. This treatment effect of 0.12 points did however not meet the prespecified minimal clinically relevant difference of 0.25 points. Among the 767 randomized patients, 539 had mild symptoms and 228 patients had moderate to severe HDM allergic symptoms, defined by a mean baseline daily symptom score (dSS(n)) of at least 2. Post hoc analysis of the clinical data, focusing on this subgroup of patients with moderate to severe symptoms, revealed a significant treatment effect for the primary endpoint, with a clinically meaningful reduction of −0.39 points (95% CI, −0.64 to −0.13; p = 0.0031) thereby surpassing the minimal prespecified difference of 0.25 points. No additional safety concerns were observed in the moderate to severe symptom group compared with the minor symptom group.

Conclusion

Treatment with the tested SCIT‐product at a dose of 50,000 AUeq/mL was safe and well tolerated. The primary outcome was not met, with no significant difference observed between the active and placebo groups. A likely explanation might be the inclusion of mainly patients with mild symptoms of rhino conjunctivitis (539 of in total 767 randomized subjects). Post hoc analysis, however, indicated that SCIT was effective in the subgroup of patients with moderate to severe disease, suggesting that the overall study outcome may have been influenced by the inclusion of a large proportion of patients with only mild symptoms of HDM‐induced rhino‐conjunctivitis. As a consequence, reconfirming efficacy requires adequate baseline symptom severity, especially in HDM allergic patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Desensitization, ImmunologicPyroglyphidaeAntigens, DermatophagoidesHypersensitivityAllergensHumansAdultMaleFemaleMiddle AgedAnimalsTreatment OutcomeInjections, SubcutaneousYoung AdultAdolescentAged

Stichwörter der Autor:innen

allergen immunotherapy (AIT)allergic rhinoconjunctivitiscombined symptom and medication score (CSMS)efficacyhouse dust mites (HDM)pivotal phase III trialsafetysubcutaneous immunotherapy (SCIT)

Substanzen

Antigens, DermatophagoidesAllergens

Autor:innen und Institutionen

  • ENT-Dep, University of Muenster, Muenster, Germany.
  • HAL Allergy B.V., Leiden, the Netherlands.
  • Division of Allergy and Immunology, Department of Dermatology, Venerology and Allergy, Charité Universitätsmedizin Berlin, Berlin, Germany.
  • Section of Rhinology and Allergy, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany.
  • Department of Clinical Immunology, Faculty of Medicine of Wroclaw Medical University, Wroclaw, Poland.
  • ALL-MED Medical Research Institute, Wroclaw, Poland.

ORCID-Profile: Claus Bachert, Rimko Ten Have, Donghui Yu, Margitta Worm, Oliver Pfaar, Marek Jutel, Andrzej Bozek

Förderung

  • HAL Allergy

Zitieren

APA

Bachert, C., Hoogeveen, H., Ten Have, R., Yu, D., Worm, M., Pfaar, O., Jutel, M., Distler, A., Bozek, A., Opstelten, D. J., Narkus, A., & van Ree, R. (2025). Subcutaneous Allergen Immunotherapy in Adults Allergic to House Dust Mites: A Phase 3 Randomized Controlled Trial. Allergy. https://doi.org/10.1111/all.70063

Vancouver

Bachert C, Hoogeveen H, Ten Have R, Yu D, Worm M, Pfaar O, et al. Subcutaneous Allergen Immunotherapy in Adults Allergic to House Dust Mites: A Phase 3 Randomized Controlled Trial. Allergy. 2025. doi:10.1111/all.70063

BibTeX
@article{Bachert2025,
  author = {Bachert, Claus and Hoogeveen, Hans and Ten Have, Rimko and Yu, Donghui and Worm, Margitta and Pfaar, Oliver and Jutel, Marek and Distler, Andreas and Bozek, Andrzej and Opstelten, Dirk-Jan and Narkus, Annemie and van Ree, Ronald},
  title = {Subcutaneous Allergen Immunotherapy in Adults Allergic to House Dust Mites: A Phase 3 Randomized Controlled Trial},
  journal = {Allergy},
  year = {2025},
  doi = {10.1111/all.70063}
}
Kostenlos starten →